Table 1 JOSD1 Expression and Clinicopathological Features of HNSCC
Clinicopathological Features | JOSD1 expression | Total | P value | |
|---|---|---|---|---|
Low | High | |||
Gender | ||||
 Male | 13 (38.2%) | 21 (61.8%) | 34 | 0.256 |
 Female | 5 (62.5%) | 3 (37.5%) | 8 | |
Age | ||||
 ≥ 60 | 9 (39.1%) | 14 (60.9%) | 23 | 0.591 |
 < 60 | 9 (47.4%) | 10 (52.6%) | 19 | |
Smoke | ||||
 Yes | 10 (40.0%) | 15 (60.0%) | 25 | 0.650 |
 No | 8 (47.1%) | 9 (52.9%) | 17 | |
Drink | ||||
 Yes | 6 (30.0%) | 14 (70.0%) | 20 | 0.108 |
 No | 12 (54.5%) | 10 (45.5%) | 22 | |
T stage | ||||
 T1–T2 | 14 (58.3%) | 10 (41.7%) | 24 | 0.019* |
 T3–T4 | 4 (22.2%) | 14 (77.8%) | 18 | |
N stage | ||||
 N0 | 12 (52.2%) | 11 (47.8%) | 23 | 0.179 |
 N1–3 | 6 (31.6%) | 13 (68.4%) | 19 | |
Clinical stage | ||||
 I–II | 11 (57.9%) | 7 (42.1%) | 18 | 0.038* |
 III–IV | 7 (21.7%) | 17 (78.3%) | 24 | |
Histological grade | ||||
 G1 | 5 (35.7%) | 9 (64.3%) | 14 | 0.532 |
 G2 | 11 (52.4%) | 10 (47.6%) | 21 | |
 G3 | 2 (28.6%) | 5 (71.4%) | 7 | |
Resistance | ||||
 PR | 8 (72.7%) | 3 (27.3%) | 11 | 0.048* |
 PD/SD | 10 (32.3%) | 21 (67.7%) | 31 | |